

POSTER PRESENTATION

Open Access

P324: Management of risk in a country in crisis: hepatonephritis cases related to artemisinin-based combinations therapy

T Daubrey Potey*, M Kamagaté, H Dié-Kacou

From 2nd International Conference on Prevention and Infection Control (ICPIC 2013)
Geneva, Switzerland. 25-28 June 2013

Objectives

To analyze risk management when occurred hepatonephritis cases related to Artemisinin-based Combinations Therapy.

Methods

A technical committee of management of hepatonephritis cases has been set up by the health ministry. The terms of references were: 1) state of knowledges on the subject from the pharmacovigilance database of Côte-d'Ivoire; 2) Carrying out of an investigation in public and private hospitals; 3) start -up a plan of communication for the health professionals and population.

Results

States of knowledges: for 10 years, serious Adverse Drug reactions have been notified (57%), like black fever, hepatonephritis and serious hepatitis cases related to any antimalarial monotherapies : amodiaquin, artemisinin derivatives and quinine. Retrospective study: we collected 100 files. The principal damage was hepatic (63%), hepatorenal (26%) and hematologic (19%). Antimalarial drugs implicated were: quinine (30,4%), artemether-lumefantine (21,4%) and artesunate-sulfamethopyrazine (13,6%). Prospective study: We have analyzed 25 cases over 3 months of investigation.

Conclusion

Start-up of a plan of communication: we drafted and sent an alarm note and recommendations of good use of anti-malarial combinotherapies to prescribers and dispensers.

Disclosure of interest

None declared.

Published: 20 June 2013

doi:10.1186/2047-2994-2-S1-P324

Cite this article as: Daubrey Potey et al.: P324: Management of risk in a country in crisis: hepatonephritis cases related to artemisinin- based combinations therapy. *Antimicrobial Resistance and Infection Control* 2013 **2**(Suppl 1):P324.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

